toumei ../../image Congress Report

Aventis Pharma/Daiichi Pharmaceutical Co., Ltd. Joint-Sponsored Symposium at the 4th ECC 2002

Chairman: Peter Ball, UK

The 4th European Congress of Chemotherapy and Infection (ECC) was held, this year, in conjunction with the 9th Biennial Conference on Antiinfective Agents and Chemotherapy in Paris, France between May 4th and 7th, 2002. ECC is the biennial meeting of the Federation of the European Societies for Chemotherapy and Infection, which consists of 43 different societies. This year's meeting focused on the latest advances in clinical and laboratory research in chemotherapy and the treatment of infection, and attracted delegates from a number of disciplines, including clinical microbiologists, chemotherapy experts, infection-control experts, biomedical researchers, postgraduate students and physicians.

A series of expert lectures at the meeting covered the important area of pneumococcal respiratory infections. Connected to this is the increasing problem of resistance of Streptococcus pneumoniae and other pathogens to traditional treatments. Exciting data on the widespread activity and low incidence of resistance to fluoroquinolones was presented, indicating that these agents may be useful alternative therapies in problematic cases of respiratory infections.

This report summarizes the data presented at an Aventis-sponsored symposium on May 5th, 2002, which discussed the increasing problem of S. pneumoniae resistance in respiratory infections. Current data was presented that confirmed the important role of levofloxacin and other fluoroquinolones in the management of respiratory infections.

toumei ../../image    
  To read the reports click on the title.
toumei ../../image    
  Chairman's introduction.
toumei ../../image   Lunch followed by Chairman's introduction.
toumei ../../image    

Epidemiology of Streptococcus pneumoniae infections and resistance
Rafael Canton MD
Hospital Ramn y Cajal, Madrid, Spain
toumei ../../image   Biography     
toumei ../../image    
Activity of fluoroquinolones and levofloxacin in pneumococal infections and against resistant isolates
Andr Bryskier MD
Aventis Pharma, France
toumei ../../image   Biography     
toumei ../../image    
Clinical results with fluoroquinolones and levofloxacin use
Peter Ball BSc MB ChB
University of St Andrews, Scotland, UK
toumei ../../image   Biography     
toumei ../../image    
toumei ../../image    


©This highlight has been developed by Diagnosis Healthcare Communications


  ©1998- BIOMEDIS International, Ltd. All rights reserved. Reproduction in any manner in whole or part prohibited.
Last updated May 6, 2002